Katelyn O'Brien, PharmD, says a shared view of cardio-kidney-metabolic syndrome lets pharmacists unify care across endocrinology, cardiology, and nephrology.

Kelsey Norman, PharmD, says pharmacists' longer visits and collaborative practice agreements make them well positioned to get patients to low-density lipoprotein (LDL) goals.

Anthony Ishak, PharmD, explains how the PREVENT risk estimator helps pharmacists calibrate dose intensity and move stage 2 patients to combination therapy.

The expanded approval of lenolisib made it the first approved treatment for pediatric patients with activated phosphoinositide 3-kinase delta syndrome.

Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.

Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.